Mass High Tech -- Genzyme Corp. plans to sell its pharmaceutical intermediates business to an affiliate of the International Chemical Investors Group. Today’s announcement comes as the Cambridge biotech giant completes its $265 million cash sale of its diagnostics business to Sekisui Chemical Co, Ltd., announced in November. Both unit sales tie into current and potential treatments for Gaucher disease.
